Century Therapeutics Stock Today
| IPSC Stock | USD 0.70 0.01 1.41% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Century Therapeutics is trading at 0.7 as of the 25th of February 2025, a 1.41 percent decrease since the beginning of the trading day. The stock's open price was 0.71. Century Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 27th of November 2024 and ending today, the 25th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of June 2021 | Category Healthcare | Classification Health Care |
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania. The company has 85.03 M outstanding shares of which 3.07 M shares are currently shorted by private and institutional investors with about 5.58 trading days to cover. More on Century Therapeutics
Moving against Century Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Century Stock Highlights
| CEO Director | PharmD MBA | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsCentury Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Century Therapeutics' financial leverage. It provides some insight into what part of Century Therapeutics' total assets is financed by creditors.
| |||||
Century Therapeutics (IPSC) is traded on NASDAQ Exchange in USA. It is located in 25 North 38th Street, Philadelphia, PA, United States, 19104 and employs 152 people. Century Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 59.69 M. Century Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 85.03 M outstanding shares of which 3.07 M shares are currently shorted by private and institutional investors with about 5.58 trading days to cover.
Century Therapeutics currently holds about 378.76 M in cash with (88.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.43, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Century Therapeutics Probability Of Bankruptcy
Ownership AllocationCentury Therapeutics holds a total of 85.03 Million outstanding shares. Over half of Century Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Century Ownership Details
Century Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 991.6 K | |
| Tang Capital Management Llc | 2024-12-31 | 900 K | |
| State Street Corp | 2024-12-31 | 852.8 K | |
| Baker Bros Advisors Lp | 2024-12-31 | 797.5 K | |
| Superstring Capital Management Lp | 2024-12-31 | 463 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 357.8 K | |
| Northern Trust Corp | 2024-12-31 | 337 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 271 K | |
| Bridgeway Capital Management, Llc | 2024-12-31 | 249.7 K | |
| Bain Capital Life Sciences Investors, Llc | 2024-12-31 | 5.4 M | |
| Casdin Capital, Llc | 2024-12-31 | 5.2 M |
Century Therapeutics Historical Income Statement
Century Stock Against Markets
Century Therapeutics Corporate Management
| Michael Diem | Chief Officer | Profile | |
| Morgan Conn | Chief Officer | Profile | |
| Michael Naso | Senior Engineering | Profile | |
| Nick MD | Senior Development | Profile | |
| Kenneth JD | Head Compliance | Profile | |
| Chad Cowan | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Century Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Century Therapeutics. If investors know Century will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Century Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.83) | Revenue Per Share | Quarterly Revenue Growth 4.345 | Return On Assets | Return On Equity |
The market value of Century Therapeutics is measured differently than its book value, which is the value of Century that is recorded on the company's balance sheet. Investors also form their own opinion of Century Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Century Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Century Therapeutics' market value can be influenced by many factors that don't directly affect Century Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Century Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.